Merus to Present at the Jefferies 2019 Healthcare Conference
UTRECHT, Netherlands, June 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., President, Chief Executive Officer and Principal Financial Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019, at 10:00 a.m. ET.
A live webcast of the event will be available on the Investors and Media page of the Company's website, http://www.merus.nl. A replay of the presentation will be archived and available on the Merus website site for a limited time following the event.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information on the company and programs, please visit Merus’ website, www.merus.nl .
Investor and Media Inquiries:
Investor Relations and Corporate Communications
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Corel25.6.2019 15:02:09 CEST | Pressemeddelelse
Painter 2020 Empowers Digital Artists to Achieve Their Perfect Vision
Appian Corporation25.6.2019 15:02:09 CEST | Pressemeddelelse
Appian Announces Winners of its Annual Hackathon at Appian World
XBiotech Inc.25.6.2019 14:47:08 CEST | Pressemeddelelse
XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa
Erytech Pharma S.A.24.6.2019 23:32:28 CEST | Pressemeddelelse
ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies
Vricon24.6.2019 14:32:47 CEST | Pressemeddelelse
U.S. Army awards Vricon contract for One World Terrain
Erytech Pharma S.A.24.6.2019 07:32:40 CEST | Pressemeddelelse
ERYTECH Announces Opening of Operations at its New Princeton, NJ GMP Manufacturing Facility
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum